Efficacy and safety of rivaroxaban, colchicine, and famotidine–loratadine with specialist supportive clinical care for fatigue in patients with post-COVID-19 condition in the UK: a multisite, open-label, randomised controlled trial

Study limitation reported by the research below: “Rivaroxaban serious adverse events (5 events in 3 patients) are noted but described as unrelated to the trial drug; causality cannot be fully excluded in an open-label setting.”